Ftse Mib
38.714,52
0,63%
DAX
22.410,27
-0,05%
S&P 500
5.955,25
-0,47%
NASDAQ
19.026,39
-1,35%
Bitcoin
88.715,13
0,09%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Acceleron Pharma Inc (XLRN) Acceleron Pharma Inc (XLRN) Notizie

XLRN

Acceleron Pharma (XLRN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:XLRN
DataOraFonteTitoloSimboloCompagnia
02/12/202115:01Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(b) (15-12b)NASDAQ:XLRNAcceleron Pharma Inc
24/11/202121:48Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:XLRNAcceleron Pharma Inc
23/11/202111:21TipRanksMerck Completes Acquisition of Acceleron PharmaNASDAQ:XLRNAcceleron Pharma Inc
22/11/202115:13Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XLRNAcceleron Pharma Inc
22/11/202114:52Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XLRNAcceleron Pharma Inc
22/11/202113:02Edgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:XLRNAcceleron Pharma Inc
17/11/202120:26Business WireAvoro Capital Urges Acceleron Shareholders Not to Tender Into Merck’s Inadequate OfferNASDAQ:XLRNAcceleron Pharma Inc
17/11/202113:01Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:XLRNAcceleron Pharma Inc
09/11/202123:31Business WireAvoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck’s Inadequate OfferNASDAQ:XLRNAcceleron Pharma Inc
04/11/202121:14Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:XLRNAcceleron Pharma Inc
04/11/202121:01Business WireAcceleron Reports Third Quarter 2021 Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
28/10/202114:00Business WireAvoro Capital Issues Open Letter to Fellow Acceleron Pharma ShareholdersNASDAQ:XLRNAcceleron Pharma Inc
27/10/202113:10Business WireAcceleron Announces Third Quarter 2021 REBLOZYL® Net SalesNASDAQ:XLRNAcceleron Pharma Inc
25/10/202115:17TipRanksAcceleron Temptation: Will Shareholders Accept Merck’s Offer?NASDAQ:XLRNAcceleron Pharma Inc
20/10/202119:58Edgar (US Regulatory)Statement of Ownership: Solicitation (sc 14d9)NASDAQ:XLRNAcceleron Pharma Inc
12/10/202115:26Edgar (US Regulatory)Tender Offer Statement by Third Party (sc To-t)NASDAQ:XLRNAcceleron Pharma Inc
05/10/202118:31Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:XLRNAcceleron Pharma Inc
01/10/202122:17Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:XLRNAcceleron Pharma Inc
30/09/202122:31Edgar (US Regulatory)Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)NASDAQ:XLRNAcceleron Pharma Inc
30/09/202121:52Business WireAvoro Capital Believes Proposed Acquisition of Acceleron Pharma by Merck Undervalues Acceleron PharmaNASDAQ:XLRNAcceleron Pharma Inc
30/09/202113:34Dow Jones NewsMerck to Buy Acceleron Pharma for $11.5 BillionNASDAQ:XLRNAcceleron Pharma Inc
05/08/202122:01Business WireAcceleron Reports Second Quarter 2021 Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
28/07/202113:10Business WireAcceleron Announces Second Quarter 2021 REBLOZYL® Net SalesNASDAQ:XLRNAcceleron Pharma Inc
26/07/202113:00Business WireAcceleron to Webcast Second Quarter 2021 Financial Results on August 5, 2021NASDAQ:XLRNAcceleron Pharma Inc
11/06/202109:00Business WireBristol Myers Squibb & Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® (luspatercept-aamt) in Adults ...NASDAQ:XLRNAcceleron Pharma Inc
08/06/202113:00Business WireAcceleron to Host Virtual Research and Development (R&D) Day on June 22, 2021NASDAQ:XLRNAcceleron Pharma Inc
19/05/202114:00Business WireAcceleron Presents Preliminary Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) at...NASDAQ:XLRNAcceleron Pharma Inc
19/05/202114:00Business WireAcceleron Presents Interim Results from the Open-label Extension of the PULSAR Phase 2 Trial of Sotatercept in Patients with ...NASDAQ:XLRNAcceleron Pharma Inc
12/05/202116:57Business WireAcceleron Announces Presentations on REBLOZYL® (luspatercept-aamt) at the 2021 European Hematology Association Virtual Congr...NASDAQ:XLRNAcceleron Pharma Inc
11/05/202113:00Business WireAcceleron to Host Conference Call & Webcast to Review Clinical Trial Updates, Preclinical Presentations on Sotatercept in Pul...NASDAQ:XLRNAcceleron Pharma Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:XLRN

La tua Cronologia

BIT
EMPAB
UBS ETF IE MSCI EM Mkts ...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci